Among the thousands of pages of Dr. Anthony S. Fauci’s emails released recently by BuzzFeed News, a short note from Kristian Andersen, a virologist at the Scripps Research Institute in La Jolla, Calif., has garnered a lot of attention.

Over the past year, Dr. Andersen has been one of the most outspoken proponents of the theory that the coronavirus originated from a natural spillover from an animal to humans outside of a lab. But in the email to Dr. Fauci in January 2020, Dr. Andersen hadn’t yet come to that conclusion. He told Dr. Fauci, the government’s top infectious disease expert, that some features of the virus made him wonder whether it had been engineered, and noted that he and his colleagues were planning to investigate further by analyzing the virus’s genome.

Continue reading “Scientist Opens Up About His Early Email to Fauci on Virus Origins” →

Dr. Adam Zeman didn’t give much thought to the mind’s eye until he met someone who didn’t have one. In 2005, the British neurologist saw a patient who said that a minor surgical procedure had taken away his ability to conjure images.

Over the 16 years since that first patient, Dr. Zeman and his colleagues have heard from more than 12,000 people who say they don’t have any such mental camera. The scientists estimate that tens of millions of people share the condition, which they’ve named aphantasia, and millions more experience extraordinarily strong mental imagery, called hyperphantasia.

In their latest research, Dr. Zeman and his colleagues are gathering clues about how these two conditions arise through changes in the wiring of the brain that join the visual centers to other regions. And they’re beginning to explore how some of that circuitry may conjure other senses, such as sound, in the mind. Eventually, that research might even make it possible to strengthen the mind’s eye — or ear — with magnetic pulses.

Continue reading “Many People Have a Vivid ‘Mind’s Eye,’ While Others Have None at All” →

In December, British researchers discovered that a new variantwas sweeping through their country. When it arrived in other countries, the variant, now known as Alpha, tended to become more common in its new homes as well. By April, it had become the dominant variant in the United States, and it has remained so ever since.

Alpha’s swift success has left scientists wondering how the variant conquered the world. A new study points to one secret to its success: Alpha disables the first line of immune defense in our bodies, giving the variant more time to multiply.

Continue reading “How the ‘Alpha’ Coronavirus Variant Became So Powerful” →

As the nation edges closer to President Biden’s goal of a 70 percent vaccination rate, many people are beginning to wonder how long their protection will last.

For now, scientists are asking a lot of questions about Covid-19 booster shots, but they don’t yet have many answers. The National Institutes of Health recently announced that it has begun a new clinical trial of people fully vaccinated — with any authorized vaccine — to see whether a booster of the Moderna shot will increase their antibodies and prolong protection against getting infected with the virus.

Although many scientists estimate that the Pfizer-BioNTech, Moderna and Johnson & Johnson vaccines authorized in the United States will last at least a year, no one knows for sure. It’s also unclear whether emerging variants of the coronavirus will change our vaccination needs.

Continue reading “We’ll Probably Need Booster Shots for Covid-19. But When? And Which Ones?” →

The German company CureVac said on Friday that its Covid-19 vaccine had passed its first interim analysis, but that it was not yet ready to share data on how well it protects against infection. The shot could be cheaper and more accessible to low-income countries that lack vaccines.

The company said that an independent Data Safety Monitoring Board found no safety concerns. But the board did not share any efficacy data, suggesting that it’s not yet clear just how much protection the vaccine provides.

“The trial will continue to collect sufficient data in order to conduct statistically significant efficacy analysis,” the company said in its statement.

Continue reading “Early analysis suggests that another mRNA vaccine is safe, but its effectiveness isn’t yet known.” →